摘要
HomeRadiologyVol. 299, No. 3 PreviousNext Reviews and CommentaryFree AccessEditorialMultiparametric MRI of the Prostate: Beyond Cancer Detection and StagingDaniel N. Costa Daniel N. Costa Author AffiliationsFrom the Department of Radiology, UT Southwestern Medical Center, 2201 Inwood Rd, Dallas, TX 75390.Address correspondence to the author (e-mail: [email protected]).Daniel N. Costa Published Online:Apr 13 2021https://doi.org/10.1148/radiol.2021204506MoreSectionsPDF ToolsImage ViewerAdd to favoritesCiteTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinked In See also the article by Harmon et al in this issue.Dr Costa is an associate professor in the body MRI section of the department of radiology at the University of Texas Southwestern Medical Center. His research interests focus on prostate cancer imaging, targeted biopsies, and focal therapy. He is a fellow of the Society for Advanced Body Imaging and serves on National Institutes of Health study sections.Download as PowerPointOpen in Image Viewer Prostate cancer is a common and heterogeneous condition. It ranges from indolent low-grade disease—which many experts argue would be better left undetected—to lethal forms warranting early detection and prompt treatment. Despite a 5-year survival rate of 98%, it represents the second most common cause of cancer-specific death in men (1). More men with low-risk disease are adopting active surveillance, which is encouraging (2). However, up to 50% of men with indolent forms of the disease undergo radical prostatectomy or radiation therapy (3). The uncertainty of active surveillance and the legal, cultural, and financial forces partly explain this bias toward treatment (4). Many men with presumed localized prostate cancer who undergo surgery experience biochemical recurrence. This indicates that local surgical treatment alone may not provide adequate disease control.Given the varying aggressiveness of prostate cancer, the disconnect between predicted pretreatment risk and posttreatment actual risk, and the potential morbidity of available treatment options, patients with newly diagnosed prostate cancer need better tools. These tools should provide baseline risk stratification and should tailor treatment strategies to individual tumor characteristics. In current clinical practice, prostate-specific antigen, digital rectal examination, and biopsy results (ie, Gleason grade group, number of biopsy cores, and percentage of core length containing cancer) are the basis for patient treatment (5). Each of these tools has known limitations. These limitations include poor sensitivity and/or specificity of prostate-specific antigen and digital rectal examinations and sampling issues with transrectal US–guided systematic prostate biopsy. During a systematic biopsy, multiple cores are obtained from the various sextants of the prostate in an attempt to detect a potential cancer. Rather than systemic biopsy, targeted prostate biopsy uses multiparametric MRI to identify suspicious regions, which allows targeted biopsy samples. The rapid adoption of targeted prostate biopsy tackles the shortcomings of systematic sampling (6) and has been one of the cornerstones for the growing use of MRI in patients suspected of having prostate cancer.In this issue of Radiology, Harmon and colleagues (7) found features at preoperative MRI associated with increased rates of biochemical recurrence after radical prostatectomy. Although different definitions exist, biochemical recurrence refers to the persistent detection of prostate-specific antigen after surgery, suggesting the presence of residual or recurrent tumor. Biochemical recurrence correlates with worse outcomes. Thus, men with biochemical relapse often need to undergo adjuvant therapy (8). The authors assessed several imaging variables in this retrospective case-control study. At univariable analysis, they found a positive correlation between biochemical recurrence rates and the following imaging variables: (a) Prostate Imaging Reporting and Data System (version 2) score of 5 (hazard ratio [HR], 2.10; P = .04), (b) index lesion burden (HR, 1.55; P = .003), and (c) grade of perceived suspicion for extraprostatic extension of 1–3 (HR, 2.18; P = .02). Harmon and colleagues (7) also investigated the association between biochemical recurrence and the expression of five prostate cancer–related oncoproteins using immunohistochemistry analysis of preoperative biopsy specimens. Several genomic abnormalities have been reported or proposed as markers of prostate cancer aggressiveness (9). Among those evaluated by the authors, p53 positivity only correlated with higher rates of biochemical recurrence in univariable analysis (moderate [2+ intensity], HR, 1.92, P = .12; strong [3+ intensity], HR, 3.46, P = .005). The authors include an analysis with data available before surgery (ie, MRI and biopsy) and another with data available after surgery, including surgical outcomes such as pathology-proven extraprostatic extension and margin positivity. However, the preoperative data may have more clinical impact because they emulate the information available at the moment when therapeutic decisions are made. Multivariable analysis indicated that MRI-based level of suspicion for extraprostatic extension (HR, 2.19; P = .02) and p53 positivity (intensity staining 2+ and 3+, HR, 2.22; P = .04) were the only variables significantly associated with biochemical recurrence.This study by Harmon and colleagues (7) may foster data-driven therapeutic decisions in men with newly diagnosed prostate cancer. The current primary use of MRI in prostate cancer is for triaging of patients and for identification of areas for sampling before biopsy. However, the role of MRI in local staging and preoperative planning has long been recognized. The results from this study encourage the use of specific imaging and immunohistochemical findings to select patients better suited for definitive treatment options aiming beyond local disease control.The study had some limitations. First, the use of a single highly experienced radiologist may reduce generalizability and precludes assessment of reproducibility. Second, some of the proposed imaging markers and most, if not all, of the immunohistochemical markers are not routinely measured or performed in clinical practice. This affects the immediate applicability of these findings. Third, because of the heterogeneity of imaging protocols, the authors were not able to properly evaluate some recognized quantitative imaging markers of disease aggressiveness, such as apparent diffusion coefficient values or other diffusion weighted imaging–based metrics. Finally, although biochemical recurrence is a sign of disease recurrence after surgery, some controversy remains as it does not always result in the development of metastatic disease or cancer-specific mortality (10).The pursuit of meaningful personalized medicine tailoring treatment options to the individual tumor biologic characteristics is an area of active research. Larger multicenter multireader studies replicating and building on these results will be necessary before translation to clinical practice. It will be of particular interest to investigate if the higher rate of biochemical recurrence is a definite marker of poor prognosis after surgery. This requires validation by wider accepted end points such as cancer-specific mortality. Also of great interest is whether tumors with those prognostic features experience higher biochemical recurrence rates with nonsurgical treatment options. Future studies may examine whether it is possible to combine these imaging and molecular prognostic markers into common prognostic nomograms.In conclusion, this study suggests that certain multiparametric MRI and molecular features offer individualized information regarding the risk of biochemical recurrence. This improved prediction of postoperative outcomes may optimize the selection of men who will benefit from more comprehensive treatment regimens.Disclosures of Conflicts of Interest: D.N.C. disclosed no relevant relationships.References1. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence - SEER 9 Regs Research Data, Nov 2018 Sub (1975-2016).https://seer.cancer.gov/data-software/documentation/seerstat/nov2018/. Published 2019. Accessed December 3, 2020. Google Scholar2. Cooperberg MR, Carroll PR. Trends in Management for Patients With Localized Prostate Cancer, 1990-2013. JAMA 2015;314(1):80–82. Crossref, Medline, Google Scholar3. Kinsella N, Helleman J, Bruinsma S, et al. Active surveillance for prostate cancer: a systematic review of contemporary worldwide practices. Transl Androl Urol 2018;7(1):83–97. Crossref, Medline, Google Scholar4. Singh PB, Ahmed HU, Emberton M. Active surveillance: is there a need for better risk stratification at the outset?. J Clin Oncol 2010;28(28):e513;author reply e514. Crossref, Medline, Google Scholar5. Sanda MG, Cadeddu JA, Kirkby E, et al. Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part I: Risk Stratification, Shared Decision Making, and Care Options. J Urol 2018;199(3):683–690. Crossref, Medline, Google Scholar6. Siddiqui MM, Rais-Bahrami S, Turkbey B, et al. Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. JAMA 2015;313(4):390–397. Crossref, Medline, Google Scholar7. Harmon SA, Gesztes W, Young D, et al. Prognostic Features of Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy Based on Multiparametric MRI and Immunohistochemistry Analysis of MRI-guided Biopsy Specimens. Radiology 2021.https://doi.org/10.1148/radiol.2021202425. Published online April 13, 2021. Link, Google Scholar8. Stephenson AJ, Kattan MW, Eastham JA, et al. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol 2006;24(24):3973–3978. Crossref, Medline, Google Scholar9. Barbieri CE, Bangma CH, Bjartell A, et al. The mutational landscape of prostate cancer. Eur Urol 2013;64(4):567–576. Crossref, Medline, Google Scholar10. Tourinho-Barbosa R, Srougi V, Nunes-Silva I, et al. Biochemical recurrence after radical prostatectomy: what does it mean?. Int Braz J Urol 2018;44(1):14–21. Crossref, Medline, Google ScholarArticle HistoryReceived: Dec 5 2020Revision requested: Dec 14 2020Revision received: Dec 14 2020Accepted: Dec 16 2020Published online: Apr 13 2021Published in print: June 2021 FiguresReferencesRelatedDetailsAccompanying This ArticlePrognostic Features of Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy Based on Multiparametric MRI and Immunohistochemistry Analysis of MRI-guided Biopsy Specimens13 Apr 2021RadiologyRecommended Articles Prostate Cancer: PI-RADS Version 2 Helps Preoperatively Predict Clinically Significant CancersRadiology2016Volume: 280Issue: 1pp. 108-116What Are We Missing? False-Negative Cancers at Multiparametric MR Imaging of the ProstateRadiology2017Volume: 286Issue: 1pp. 186-195The Current State of MR Imaging–targeted Biopsy Techniques for Detection of Prostate CancerRadiology2017Volume: 285Issue: 2pp. 343-356Diffusion-weighted Imaging of Prostate Cancer: Revisiting Occam's RazorRadiology2019Volume: 291Issue: 2pp. 398-399Revisiting Prostate Cancer Recurrence with PSMA PET: Atlas of Typical and Atypical Patterns of SpreadRadioGraphics2019Volume: 39Issue: 1pp. 186-212See More RSNA Education Exhibits The Whole is Greater Than the Sum of Its Parts: WB-MRI in Metastatic Prostate CancerDigital Posters2018Magnetic Resonance Imaging of the Prostate Before and After Focal TherapyDigital Posters2020Same Day Prostate MRI and MRI/US Fusion Biopsy Service at Our Institution: How We Do ItDigital Posters2020 RSNA Case Collection Anterior transition zone prostate adenocarcinomaRSNA Case Collection2020Peripheral Zone Prostate Cancer with PseudocapsuleRSNA Case Collection2022Locally advanced, metastatic prostate adenocarcinomaRSNA Case Collection2020 Vol. 299, No. 3 Metrics Downloaded 984 times Altmetric Score PDF download